Novel perspectives on MSLN-targeted cancer therapy: from molecular mechanisms to clinical translation
Zhendong Wu, Xuefei Fu, Yuan Feng, Rong Zeng, Huan Qin, Kai Yao · 2025
Read Novel perspectives on MSLN-targeted cancer therapy: from molecular mechanisms to clinical translation by Zhendong Wu, Xuefei Fu, Yuan Feng, Rong Zeng, Huan Qin, Kai Yao (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12710932.txt.
Description
A protein that studs the surface of many tumors but barely shows on healthy tissue makes a tempting target for cancer drugs. Zhendong Wu and five co-authors review that target, mesothelin, in a 2025 paper. The protein helps tumors grow, spread, and hide from the immune system through several signaling pathways.
Four attack styles dominate the field: drug-carrying antibodies, cancer vaccines, tumor-killing viruses, and engineered T cells. Each has shown promise in lab work and early patient trials. Two problems dog all of them. The protein's outer part can be shed, soaking up drugs before they reach the tumor, and its signaling role is still not fully mapped. The review walks from the gene and protein structure through each therapy style, ending with what must be solved before these treatments can go wide.
Catalog record
| CREATOR | Zhendong Wu, Xuefei Fu, Yuan Feng, Rong Zeng, Huan Qin, Kai Yao |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 78 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |